The Influenza Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Influenza Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Influenza Market.

Some of the key takeaways from the Influenza Pipeline Report:

Companies across the globe are diligently working toward developing novel Influenza treatment therapies with a considerable amount of success over the years. 
Influenza companies working in the treatment market are Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc., GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Pneumagen Ltd., Ena Respiratory, Moderna, Inc., Valenta Pharmaceuticals, Raynovent Co., and others, are developing therapies for the Influenza treatment 
Emerging Influenza therapies in the different phases of clinical trials are- LUNAR-FLU, naNO-Flu, UniFlu, CC-42344, GSK4382276A, CVSQIV, ALVR 106, mRNA-1073. OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others are expected to have a significant impact on the Influenza market in the coming years.   
In June 2022, The first participants in a Phase III study of the Company’s potential seasonal influenza vaccine (mRNA-1010) have been dosed, according to a statement from Moderna, Inc. A total of 6,000 people from nations in the Southern Hemisphere are anticipated to participate in the trial
In July 2022, Through the creation of entirely synthetic CD8+ T cell Adaptive Vaccines, Emergex Vaccines Holding Limited announced the production of its universal/pandemic influenza vaccine, which is prepared for Phase I clinical trials
CureVac has administered the first dose of the modified influenza vaccine candidate FLU SV mRNA that was created in conjunction with GSK for a Phase I research. The investigation comes after the launch of a Phase I research in February 2022 to assess CVSQIV, a candidate for a multivalent influenza vaccine, at clinical locations in Panama. It is anticipated that the combined data set from the two investigations will be reported
In June 2022, The first participants in a Phase III study of the Company’s potential seasonal influenza vaccine (mRNA-1010) have been dosed, according to Moderna, Inc. A total of 6,000 people from nations in the Southern Hemisphere are anticipated to participate in the trial. In this Phase III randomised, observer-blind study, adults aged 18 and older will be tested to determine the safety and immunological non-inferiority of mRNA-1010 to a licenced seasonal influenza vaccine
In April 2022, The COVID-Influenza Combination Vaccine (CIC) Phase I/II clinical trial’s preliminary results were made public by Novavax, Inc. The COVID-19 vaccine, NVX-CoV2373, and the quadrivalent influenza vaccine candidate from Novavax are combined to form the CIC. The CIC study demonstrated that developing a combination vaccination is feasible, well-tolerated, and immunogenic
In July 2021, The first participant in Moderna’s Phase I/II study of its quadrivalent seasonal flu mRNA vaccine received a dose. The safety, reactogenicity, and immunogenicity of mRNA-1010, a potential seasonal influenza vaccine from Moderna, were assessed in this Phase I/II randomised, stratified, observer-blind, dose-ranging research in healthy persons aged 18 and older in the US

Influenza Overview

The upper respiratory tract, including the upper and lower respiratory passageways, is affected by influenza, a contagious viral disease.It is brought on by a wide variety of influenza viruses. Some of these viruses are exclusive to certain species, while others can infect humans. Respiratory droplets released from the mouth and respiratory system during coughing, talking, and sneezing are the main means of transmission for these viruses.

Get a Free Sample PDF Report to know more about Influenza Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/influenza-pipeline-insight

Emerging Influenza Drugs Under Different Phases of Clinical Development Include:

LUNAR-FLU: Arcturus Therapeutics
naNO-Flu: Emergex Vaccines
UniFlu: Emergent Biosolutions
CC-42344: Cocrystal Pharma Inc.
GSK4382276A: GlaxoSmithKline
SAB-176: SAB Biotherapeutics
INNA-051: ENA Respiratory Pty Ltd
CODA-VAX H1N1: Codagenix
ALVR106: AlloVir
CVSQIV: CureVac AG
ALVR 106: AlloVir
mRNA-1073: Moderna
OVX836: OSIVAX
Neumifil: Pneumagen Ltd.
INNA-051: Ena Respiratory
mRNA-1010: Moderna, Inc.
XC-221: Valenta Pharmaceuticals
ZSP1273: Raynovent Co., Ltd

Route of Administration

Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Influenza Pipeline Therapeutics Assessment

Influenza Assessment by Product Type
Influenza By Stage and Product Type
Influenza Assessment by Route of Administration
Influenza By Stage and Route of Administration
Influenza Assessment by Molecule Type
Influenza by Stage and Molecule Type

DelveInsight’s Influenza Report covers around 120+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Influenza product details are provided in the report. Download the Influenza pipeline report to learn more about the emerging Influenza therapies

Some of the key companies in the Influenza Therapeutics Market include:

Key companies developing therapies for Influenza are – Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Cidara Therapeutics, Inc., Medicago, Sanofi, Translate Bio, Arcturus Therapeutics, Inc., BiondVax Pharmaceuticals, Adagio Therapeutics, Virpax Pharmaceuticals, Blue Water Vaccines, SINOVAC, PDS Biotechnology, Pneumagen, Abivax, Seqirus, ExpreS2ion Biotechnologies, Vivaldi Biosciences, Ethris, GC Biopharma, AIM ImmunoTech, Eyam Vaccines And Immunotherapeutics, SyneuRx, and others

Influenza Pipeline Analysis:

The Influenza pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Influenza with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza Treatment.
Influenza key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Influenza Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Influenza market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Influenza drugs and therapies

Influenza Pipeline Market Drivers

Increasing awareness by government authorities, increasing clinical trials for new product development, increase in investment by leading market players are some of the important factors that are fueling the Influenza Market.

Influenza Pipeline Market Barriers

However, increasing awareness by government authorities, increasing clinical trials for new product development, increase in investment by leading market players and other factors are creating obstacles in the Influenza Market growth.

Scope of Influenza Pipeline Drug Insight    

Coverage: Global
Key Influenza Companies: Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc., GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Pneumagen Ltd., Ena Respiratory, Moderna, Inc., Valenta Pharmaceuticals, Raynovent Co., and others
Key Influenza Therapies: LUNAR-FLU, naNO-Flu, UniFlu, CC-42344, GSK4382276A, CVSQIV, ALVR 106, mRNA-1073. OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others
Influenza Therapeutic Assessment: Influenza current marketed and Influenza emerging therapies
Influenza Market Dynamics: Influenza market drivers and Influenza market barriers 

Request for Sample PDF Report for Influenza Pipeline Assessment and clinical trials

Table of Contents

1

Influenza Report Introduction

2

Influenza Executive Summary

3

Influenza Overview

4

Influenza- Analytical Perspective In-depth Commercial Assessment

5

Influenza Pipeline Therapeutics

6

Influenza Late Stage Products (Phase II/III)

7

Influenza Mid Stage Products (Phase II)

8

Influenza Early Stage Products (Phase I)

9

Influenza Preclinical Stage Products

10

Influenza Therapeutics Assessment

11

Influenza Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Influenza Key Companies

14

Influenza Key Products

15

Influenza Unmet Needs

16 

Influenza Market Drivers and Barriers

17

Influenza Future Perspectives and Conclusion

18

Influenza Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services